Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Capital Expenditures (2017 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Capital Expenditures for 11 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 171.83% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 10.27% year-over-year, with the annual reading at $1.5 million for FY2025, 10.27% down from the prior year.
  • Capital Expenditures hit $1.4 million in Q4 2025 for STRATA Skin Sciences, up from -$40000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.5 million in Q3 2021 to a low of -$740000.0 in Q2 2021.
  • Historically, Capital Expenditures has averaged $775600.0 across 5 years, with a median of $702000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 212.3% in 2022 and later plummeted 164.52% in 2025.
  • Year by year, Capital Expenditures stood at $1.1 million in 2021, then skyrocketed by 50.35% to $1.7 million in 2022, then increased by 1.12% to $1.7 million in 2023, then crashed by 70.66% to $504000.0 in 2024, then surged by 171.83% to $1.4 million in 2025.
  • Business Quant data shows Capital Expenditures for SSKN at $1.4 million in Q4 2025, -$40000.0 in Q3 2025, and -$61000.0 in Q2 2025.